Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SynKIR-110 in Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
NCT05568680Phase 1Recruiting
- Sponsor
- Verismo Therapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SynKIR-110 in ovarian cancer, cholangiocarcinoma (CCA), mesothelioma and 2 more, sponsored by Verismo Therapeutics. Primary endpoint: Safety and Feasibility of SynKIR-110 at 12 months. Started Mar 2023; status: recruiting.
02
Drugs
SynKIR-110
03
Conditions
ovarian cancercholangiocarcinoma (CCA)mesotheliomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05568680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568680.